.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Bladder cancer presents a clinical paradox where men suffer higher incidence but women face worse outcomes. However, recent advances in bladder cancer gene expression research now provide clarity on these differences. A study of 51 patients used transcriptome sequencing to compare tumor tissues with healthy mucosa. The results highlight a major divergence in how the disease manifests at a molecular level between sexes.
The research revealed that males have far more upregulated genes in tumor tissues compared to females. Specifically, the study identified 3,989 genes unique to male patients, while only 753 were unique to females. Male-specific expression patterns linked predominantly to cell cycle regulation and androgen receptor signaling. In contrast, female-specific patterns showed significant enrichment in immune-related pathways. These pathways include lymphocyte differentiation and leukocyte activation, which may influence how women respond to immunotherapy. Notably, overwhelmingly more upregulated genes appeared in male tissues than in female tissues during the comparison.
Notably, a two-factor interaction model pinpointed S100A14 as a critical sex-dependent gene. This protein-coding gene showed a significant interaction effect, suggesting it functions differently in male and female bladders. Furthermore, genes like GJB2 and DSC2 also showed probable sex-dependent interactions. These findings are essential because they provide a foundation for precision medicine. Therefore, doctors can potentially use these biomarkers to tailor surveillance and treatment plans more effectively. Indeed, the identification of these unique markers could pave the way for gender-specific therapeutic approaches.
Ultimately, this research underscores the necessity of considering biological sex in urological oncology. While clinicians currently use similar protocols for both genders, the molecular evidence suggests a need for sex-specific management. Future studies must validate these findings to improve survival rates and reduce recurrence for all bladder cancer patients.
Differences arise due to sex chromosomes, hormonal signaling, and distinct immune responses. These biological factors drive unique molecular pathways in tumor development, leading to different clinical presentations.
S100A14 is a protein-coding gene that exhibits a unique sex-dependent expression pattern. Researchers consider it a potential biomarker that could guide personalized treatment strategies in the future.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and should not be used for diagnosis or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Zeber-Lubecka N et al. Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing. BMC Cancer. 2026 Feb 09. doi: 10.1186/s12885-026-15666-3. PMID: 41663990.
Mun DH, Kimura S, Shariat SF, Abufaraj M. The impact of gender on oncologic outcomes of bladder cancer. Curr Opin Urol. 2019 Mar;29(2):279-285. doi: 10.1097/MOU.0000000000000606.
Yao R et al. Expression profile and functional role of S100A14 in human cancer. PeerJ. 2019 Apr 26;7:e6812. doi: 10.7717/peerj.6812.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study reveals sex-specific gene expression patterns in early-stage bladder cancer, highlighting the need for tailored management strategies for men and wo...
7 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
